<DOC>
	<DOC>NCT00368069</DOC>
	<brief_summary>This is a safety and efficacy study of Keppra® extended release formulation - XR in patients with epilepsy.</brief_summary>
	<brief_title>A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<criteria>Patients with a confirmed diagnosis of refractory epilepsy Patients must be receiving 1 3 concomitant AntiEpileptic Drugs (AED). Female patients without childbearing potential. Female patients with childbearing potential are eligible if they use a medically accepted nonhormonal contraceptive method. Seizures occurring in clusters Status epilepticus within 3 months of Visit 1. History of nonepileptic seizures. Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients. Pregnant or lactating women. Any woman with childbearing potential who is not using a medically accepted, nonhormonal method of birth control.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Keppra® XR</keyword>
	<keyword>Levetiracetam XR</keyword>
	<keyword>Extended release</keyword>
</DOC>